New treatment for Alzheimer’s

Posted byGervaisPosted inUncategorized

Or maybe, alternatively, Alzheimer’s disease prevention

The deluge of scientific innovations it is still going. We continue to be bombarded with scientific articles, detailing new modifiers and new treatments for Alzheimer’s disease, designed via tremendous effort and produced at stupendous cost: most are ineffective. However occasionally, a report hints at a possible solution.

Encouraging news (? Maybe)

One recent effort, regarding “”ALZ-801”, otherwise known as “Valitramiprosate”, was posted by Steve Bryson, PhD, in “Alzheimer’s news today”, on 22 September, 2023. At that time, Dr. Bryson reported a reduction of serum beta-amyloid and tau by 4%, with slowing of shrinkage of the hippocampus by 28% and a significantly reduced rate of cognitive decline.

A “Phase 3 topline readout in 3Q 2024” has now been announced.

Now, following a two-year safety and efficacy trial in 84 adults with early, APOE4-positive Alzheimer’s, Valitramiprosate has been reported by ALZHEON, as “Potentially the first oral disease-modifying treatment for Alzheimer’s disease, with no increased risk of ARIA (Amyloid-Related Imaging Abnormalities)”.

The company’s claim:

“Valitramiprosate is well differentiated from plaque-clearing antibodies, due to its novel mechanism of action, oral administration and potential efficacy in a genetically targeted population: it could be the first oral disease modifying drugs for Alzheimer’s disease”.

Valitramiprosate is now entering a phase 3 trial, culminating at the end of August 2024, which (if successful) will make it available to APOE4 carriers, “Over 13 million patients!”, for AD prevention.

Encouraging news, but the elephant is still in the room

Why is this elephant always in the room?

Subscribe to continue reading

Subscribe to get access to the rest of this post and other subscriber-only content.

Published by Gervais

I am a Toronto-trained Urologist. I practiced in downtown Toronto, from 1977 to 1997, when I went to Saudi Arabia as chief of Urology at the Armed Forces (teaching) hospital in Tabuk. Returning to Toronto in Y2000, I switched to family practice. In 2007, began to prescribe Hormone Restoration Therapy and in 2012, I became a member of the American Academy of Antiaging Medicine [A4M]. I successfully wrote the A4M's written examination in December, 2013 and In May, 2016 I passed the oral examination, for accreditation as a BHRT consultant. In 2014 I began BHRT practice in Collingwood, Ontario and in January, 2017, joined the Stone Tree Naturopathic Clinic. Now I am 85 and retired, but it seems wasteful to jettison my learning and experience: the medical establishment knows nothing of BHRT / Functonal medicine and I feel obliged to offer my knowledge in the interest of those who are willing to think outside the box. QUALIFICATIONS: MB, BS, (UWI), 1964. LMCC 1969. FRCSC (Urology), 1974. ECFMG 1984. Florida license [inactive], ABAARM 2016. Affiliations: CSAMM, OMA, CMA, SUSO, CUA, RCP&S/C. PRACTICE TO DATE: Consultation in Functional Medicine: Chronic Fatigue Syndrome, Fibromyalgia, Andropause, Menopause, Teenage and Postpartum Depression/Panic Attacks, Thyroid Hormone malfunction, Infertility, Sexual Dysfunction and “the Undiagnosable”. ALL ARE WELCOME to read, comment or question!